Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China’s MOH Further Standardizes Centralized Drug Purchase Online

This article was originally published in PharmAsia News

Executive Summary

China's Ministry of Health and five other state agencies recently signed an opinion draft on further standardizing centralized drug purchases in heath care institutions. According to the document, online centralized drug purchase implementation will be led by the government, with each province (including autonomous regions and municipalities) as a purchasing unit. To reduce drug distribution costs, pharmaceutical manufacturers will now be the direct bidders instead of drug wholesalers. Industry analysts believe that the policy will facilitate the establishment of a new drug purchase and sales system: first, market focus of drug manufacturing will be heightened; the drug distribution structure will change, as will sales patterns of prescription drugs. However, analysts think these will have little impact on the current drug agent model. (Click here for more - Chinese Language)

You may also be interested in...



Japan's BioComo Pursues Novel Ligand Approach To Immuno-Oncology

Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.

China Uses Old To Fight New As Repurposed Drugs Take Coronavirus Role

Several newly repurposed drugs, including a Bayer antimalarial, have shown potential benefits against the new coronavirus, promoting China to add several to its latest revised treatment guidelines.

US FDA Still Seeking Sponsor Cooperation For Oncology Label Updates

Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.

UsernamePublicRestriction

Register

SC070969

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel